GASTRORETENTIVE DRUG DELIVERY SYSTEM
Oral route of drug administration is the most preferable route because of its flexibility in formulation, ease of administration, and patient compliance. But this route has certain limitations like limited gastric residence time (GRT) for sustained drug delivery system and for the drugs which are absorb from specific region of gastrointestinal tract (GIT). To overcome these limitations, various approaches have been proposed to increase the gastric retention time of the delivery system in the upper part of gastrointestinal tract. Gastroretentive dosage form (GRDF) prolongs the GRT by targeting site-specific drug release in upper part of GIT. GRDFs enable continuous and the extended duration of drug release and improve bioavailability of drugs that have narrow therapeutic window, by this way they prolong dosing interval and increase compliance of the patient. The purpose of this article is to compile the various gastroretentive approaches. In order to understand various physiological difficulties to achieve gastric retention, we have summarized important factors controlling gastric retention. Finally the evaluation parameters of gastroretentive drug delivery systems are covered. The present review addresses briefly about the current status of various leading gastroretentive drug delivery technologies, developed until now, i.e. high density (sinking), floating, bio- or mucoadhesive, expandable, unfoldable, super porous hydrogel, magnetic systems etc. In addition, important factors controlling gastroretention, advantages and finally, future potential are discussed.
Keywords: Floating Delivery, Gastro retentive system.
2. Subhramananyam CVS, Setty JT. Laboratory manual of physical pharmaceutics. Vallabh prakashan 2002; page no 21.
3. Mathur P, Saroha K, Syan N, Verma S and Kumar V. Floating drug delivery system: An innovative acceptable approach in gastro retentive drug delivery. Scholars research library 2010; 2:257-270
4. Dixit N. Floating drug delivery system. Journal of Current Pharmaceutical Research, 2011; 7(1):6-20.
5. Vyas SP, Khar RK. Controlled drug delivery: concept and advances. Vallabh Prakashan Delhi, 2002; 1:123-231.
6. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. European Journal of Pharmaceutical Sciences, 2003; 18:37-45.
7. Khan R. Gastro retentive Drug Delivery System â€“ A Review.Int J Pharm Bio Sci, 2013; 4(2):630-646.
8. Joseph R. Robinson, Lee V. Controlled Drug Delivery, Fundamentals and Applications. 2nd Edition, Revised and Expanded, Marcell. Dekker Inc., New York (2009).
9. Sharma S and Pawar A. Low density multiparticulate system for pulsatile release of meloxicam. Int J Pharm. 2006; 313:150-158.
10. Sangekar, S., Evaluation of effect of food and specific gravity of the tablets on gastric retention time. Int.J.Pharm, 1985; 35:34-53.
11. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC and Falson F. Gastroretentive dosage forms: overview and special case of helicobactor pylori. J Control Release. 2006; 111:1-18.
12. Whitehead L, Fell JT and Collett JH. Development of a gastroretentive dosage form. Eur J Pharm Sci. 1996;4:182
13. Kawashima Y, Niwa T, Takenchi H, Hino T, Itoh Y. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci 1992; 81:135- 40
14. Moes AJ. Gastroretentive Dosage forms. Crit. Rev, Ther Drug Carrier Syst. 1993; 10:143- 195.
15. Chien YW. â€œOral drug delivery system.â€ In: Chien, Y.W. (Ed.), Novel drug delivery system, Marcel Dekker, New York, 1992; 139.
16. Jorgen F, Toftkjor H. Antacid composition.US Patent 50681095.14:815
17. Klusner EA, Lavy E, Friedman M, Hoffman A. Expandable gasrtroretentive dosage forms. J Control Release 2003; 90(2):143-62.
18. Klusner EA, Lavy E, Stepensley D, Friedman M, Hoffman A. Novel gasrtroretentive dosage form: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm Res 2002; 19:1516-23.
19. Abubakar O, Nur Jun S, Zhang. Recent progress in sustained: controlled oral delivery of captopril: an overview. Int J Pharm. 2000;139-146.
20. Jorgen F, Toftkjor H. Antacid composition.US Patent 50681095.14:815.
21. Chen J, Blevins WE, Park H, Park K. Gastric retention of superporous hydrogel composites. J Control Release 2000; 64(1-3):39-51.
22. Klusner EA, Lavy E, Friedman M, Hoffman A. Expandable gasrtroretentive dosage forms. J Control Release 2003; 90(2):143-62.
23. Nayal AS, Pandey S, Gnanarajan G, et al. Review: An Overview on Gestroretentive Floating Tablet. International Journal of Pharmaceutical and Chemical Sciences, 2013; 2(3):1357-1365.
24. Larhed AW, Artursson P, Grasjo J, Bjork K. Diffusion of drugs in native and purified gastrointestinal mucus. J Pharm Sci 1997; 86(6): 660-665.
25. Nayak AK, Malakar J, Sen KK, Gastroretentive drugdelivery technologies: Current approaches and future potential. J Pharm Educ Res, 2010; 1(2):1-10.
26. Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop. J Pharm Res 2008; 7(3):1055-66.
27. Sandinaswetha., et al; A review on gastroretentive drug delivery systems. International journal of research in Pharmaceutical and biomedical sciences, 2012; 3(3):1285-1293.
28. Soni RP, Patel AV, Patel RB, Patel MR, Patel KR, Patel NM. Gastro-retentive Drug Delivery systems: A Review. International Journal of Pharma World Research, 2011; 2(1):1-22.
29. Kshirsagar SJ, Wadekar SB, Bhalekar MR, Ughade PB, Madgulkar AR. Gastroretentive Drug Delivery System of Hydrochlorothiazide: Formulation, Optimization and In Vivo Evaluation. Asian Journal of Pharmaceutical Sciences, 2011; 6(3-4): 166-174.
30. Khan AD, Bajpal M, Floating Drug Delivery System: An Overview, Int. J. Pharm Tech Res.2010; 2:2497.
31. Nagigoti J, Shayed, Floating Drug Delivery System, Int. J. Pharm. Scien. Nano.2009; 2:595.
33. Rathod HJ, Mehta DP, Yadav JS; A review on Gastroretentive Drug Delivery Systems; PharmaTutor; 2016; 4(7):29-40
35. Maheta H, Patel MR, Patel KR, Patel MS, Review: An Overview on Floating Drug Delivery System, PharmaTutor, 2014; 2(3):61-71
36. Nayak AK, Maji R, Das B. Gastroretentive Drug Delivery systems: a review. Asian Journal of Pharmaceutical and Clinical Research. 2010;3(1):2-10.
37. Alzaher W, Shaw J, Al-kassas. Gastroretentive Formulations for Improving Oral Bioavailability of Drugs-Focus on Microspheres and their Production. Current Drug Delivery.2016; 13(5):646-651.
38. Sravya K, Kavitha K, Rupesh Kumar M, Jagdeesh Singh SD. Gastroretentive Drug Delivery Systems: A Review. Research Journal of Pharmaceutical, Biological and Chemical Sciences 2012; 3(3):966-980.
40. Parmar, G. Formulation And Evaluation Of Floating Microspheres Of Venlafaxine Hydrochloride. Pharma Science Monitor - An International Journal of Pharmaceutical Sciences. 2014; 5:10-22.
41. Chugh C, Nanda A. Gastroretentive Drug Delivery Systems - A Review. International Journal of Pharma and Bio Sciences. 2017; 8(1):62 â€“ 68.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).